Patrick Campbell

Zerlasiran reduced Lp(a) by over 90% at 60 weeks with consistent efficacy and no serious drug-related adverse events, supporting its phase 3 trial progression.

Muvalaplin, an oral treatment, reduced Lp(a) by up to 85% in a 12-week Phase 2 trial presented at AHA 2024.

Viet Le, PA-C, DMSc, breaks down new data and updates from AHA 24, spotlighting 3 specific trials and the applicability of artificial intelligence in care.

Muthiah Vaduganathan, MD, MPH, discusses the need for cardiology to embrace a role for GLP-1 receptor agonists and incretin therapies, with a focus on obesity-related HFpEF.

Stephen J. Nicholls, MD, PhD discusses the robust efficacy and tolerability of zerlasiran for Lp(a) lowering, paving the way for Phase 3 development.

Stephen Nicholls, MBBS, PhD, provides additional insight into KRAKEN trial data and the potential of muvalaplin.

Ahmad Masri, MD, MS, discusses a study from AHA 2024 detailing changing risk profiles and outcomes in trials among patients with ATTR-CM.

Ahmad Masri, MD, MS, discusses data from the FOREST-HCM trial examining effects of aficamten in patients with oHCM eligible for septal reduction therapy at baseline.

On November 12, 2024, the DOJ Antitrust Division updated its Evaluation of Corporate Compliance Programs in Criminal Antitrust Investigations (ECCP),...

With approval, acoramaidis becomes the first agent with a label specifying near-complete stabilization of TTR.